Genome-Wide Analysis of the Genetic Regulation of Gene Expression in Human Neutrophils
Investigators report an eQTL study on isolated neutrophils from 114 healthy individuals of Chinese ethnicity, identifying 21,210 eQTLs on 832 unique genes. Unsupervised clustering analysis of these eQTLs confirms their role in inflammatory responses and immunological diseases but also indicates strong involvement in dermatological pathologies. [Nat Commun] Full Article
CBP30, a Selective CBP/p300 Bromodomain Inhibitor, Suppresses Human Th17 Responses
The authors report data to support selective bromodomain blockade of the transcriptional coactivators CBP (CREB binding protein) and p300 as an alternative approach to inhibit human Th17 responses. In unbiased cellular testing on a diverse panel of cultured primary human cells, CBP30 reduced immune cell production of IL-17A and other proinflammatory cytokines. [Proc Natl Acad Sci USA] Abstract|Full Article
Human IL-21+IFN-γ+CD4+ T Cells in Nasal Polyps Are Regulated by IL-12
Scientists report that CD4+ T cells were the major IL-21-expressing cells in nasal polyp (NP) tissues and the majority of IL-21 producing CD4+ T cells co-expressed IFN-γ or IL-17A. IL-21+IFN-γ+CD4+ T cells in NP tissues exhibited the features of both Tfh and Th1 cells which co-expressed significantly higher amount of CXCR5, ICOS, PD-1, Bcl-6 and T-bet than did IL-21+IFN-γ−CD4+ T cells. [Sci Rep] Full Article
Immunopathology of Multiple Sclerosis
Investigators discuss the current understanding of multiple sclerosis immunopathology, evaluate long-standing hypotheses regarding the role of the immune system in the disease and delineate key questions that are still unanswered. [Nat Rev Immunol] Abstract
Visit our reviews page to see a complete list of reviews in the human immunology research field.
Newcastle Gets £5 Million to Boost Drug Development
Cancer Research UK’s Drug Discovery Committee has awarded Newcastle University’s Northern Institute of Cancer Research £5 million to bring more cancer drugs to clinical trials. [Cancer Research UK] Press Release
Argos Therapeutics Announces Pilot Clinical Trial of AGS-003 as Neoadjuvant Immunotherapy for Localized Renal Cell Carcinoma
Argos Therapeutics Inc. announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma. The study is being conducted at Roswell Park Cancer Institute and is designed to enroll a maximum of ten patients who will be treated with AGS-003 before nephrectomy in order to assess immune system response and tumor effects. [Argos Therapeutics Inc.] Press Release
Recruit Top Talent: Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Human Immunology News? Click here to submit!